Awad, Mark M <br/><br/>
An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).  [electronic resource] 

 -  Lung cancer (Amsterdam, Netherlands)  02 2017 
 - 126-130 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1872-8332 
<br/><br/><label>Standard No.: </label>10.1016/j.lungcan.2016.12.019  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Intravenous<br/>Adult<br/>Aged<br/>Cell Cycle Proteins--adverse effects<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local<br/>Neoplasm Staging<br/>Protein Serine-Threonine Kinases--adverse effects<br/>Proto-Oncogene Proteins--adverse effects<br/>Pteridines--administration & dosage<br/>Recurrence<br/>Small Cell Lung Carcinoma--drug therapy<br/>Smoking--epidemiology<br/>Treatment Failure<br/>Treatment Outcome<br/>Polo-Like Kinase 1